Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pharmacokinetics of propranolol in normal healthy volunteers.

Literature DB >> 881640

Pharmacokinetics of propranolol in normal healthy volunteers.

R Gomeni, G Bianchetti, R Sega, P L Morselli.

Abstract

Entities: Chemical

Mesh：

Substances：
Propranolol

Year: 1977 PMID： 881640 DOI： 10.1007/bf01065394

Source DB: PubMed Journal: J Pharmacokinet Biopharm ISSN： 0090-466X

× No keyword cloud information.

14 in total

1. Studies of the absorption and removal of propranolol in hypertensive patients during therapy.

Authors: C A Chidsey; P Morselli; G Bianchetti; A Morganti; G Leonetti; A Zanchetti
Journal: Circulation Date: 1975-08 Impact factor: 29.690

2. Contribution of the liver to overall elimination of propranolol.

Authors: C F George; M L Orme; P Buranapong; D Macerlean; A M Breckenridge; C T Dollery
Journal: J Pharmacokinet Biopharm Date: 1976-02

3. Pharmacokinetics of oral propranolol in chronic renal disease.

Authors: D T Lowenthal; W A Briggs; T P Gibson; H Nelson; W J Cirksena
Journal: Clin Pharmacol Ther Date: 1974-11 Impact factor: 6.875

4. The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat.

Authors: G H Evans; A S Nies; D G Shand
Journal: J Pharmacol Exp Ther Date: 1973-07 Impact factor: 4.030

5. Disposition of propranolol. VI. Independent variation in steady-state circulating drug concentrations and half-life as a result of plasma drug binding in man.

Authors: G H Evans; D G Shand
Journal: Clin Pharmacol Ther Date: 1973 Jul-Aug Impact factor: 6.875

6. Normalization in the fitting of data by iterative methods. Application to tracer kinetics and enzyme kinetics.

Authors: J H Ottaway
Journal: Biochem J Date: 1973-07 Impact factor: 3.857

7. A sensitive gas chromatographic method for the determination of propranolol in human plasma.

Authors: E Di Salle; K M Baker; S R Bareggi; W D Watkins; C A Chidsey; A Frigerio; P L Morselli
Journal: J Chromatogr Date: 1973-09-26

8. The disposition of propranolol. I. Elimination during oral absorption in man.

Authors: D G Shand; R E Rangno
Journal: Pharmacology Date: 1972 Impact factor: 2.547

9. Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment.

Authors: G Bianchetti; G Graziani; D Brancaccio; A Morganti; G Leonetti; M Manfrin; R Sega; R Gomeni; C Ponticelli; P L Morselli
Journal: Clin Pharmacokinet Date: 1976 Impact factor: 6.447

10. Hypotensive and renin-suppressing activities of propranolol in hypertensive patients.

Authors: G Leonetti; G Mayer; A Morganti; L Terzoli; A Zanchetti; G Bianchetti; E Di Salle; P L Morselli; C A Chidsey
Journal: Clin Sci Mol Med Suppl Date: 1975-06

19 in total

1. Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. III. Peripheral bioavailability and distribution time concepts applied to the evaluation of distribution kinetics.

Authors: P Veng-Pedersen; W R Gillespie
Journal: J Pharmacokinet Biopharm Date: 1987-06

10. Clinical pharmacokinetics of buffered propranolol sublingual tablet (Promptol™)-application of a new "physiologically based" model to assess absorption and disposition.

Authors: Yanfeng Wang; Zhijun Wang; Zhong Zuo; Brian Tomlinson; Benjamin T K Lee; Michael B Bolger; Moses S S Chow
Journal: AAPS J Date: 2013-04-19 Impact factor: 4.009

Pharmacokinetics of propranolol in normal healthy volunteers.

1. Studies of the absorption and removal of propranolol in hypertensive patients during therapy.

2. Contribution of the liver to overall elimination of propranolol.

3. Pharmacokinetics of oral propranolol in chronic renal disease.

4. The disposition of propranolol. 3. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat.

5. Disposition of propranolol. VI. Independent variation in steady-state circulating drug concentrations and half-life as a result of plasma drug binding in man.

6. Normalization in the fitting of data by iterative methods. Application to tracer kinetics and enzyme kinetics.

7. A sensitive gas chromatographic method for the determination of propranolol in human plasma.

8. The disposition of propranolol. I. Elimination during oral absorption in man.

9. Pharmacokinetics and effects of propranolol in terminal uraemic patients and in patients undergoing regular dialysis treatment.

10. Hypotensive and renin-suppressing activities of propranolol in hypertensive patients.

1. Theorems and implications of a model-independent elimination/distribution function decomposition of linear and some nonlinear drug dispositions. III. Peripheral bioavailability and distribution time concepts applied to the evaluation of distribution kinetics.

Review 2. Hepatic first-pass metabolism in liver disease.

3. Prediction of bioavailability for drugs with a high first-pass effect using oral clearance data.

4. Kinetics and cardiac effects of propranolol in humans.

5. Antiarrhythmic drugs: clinical pharmacology and therapeutic uses.

6. A standard approach to compiling clinical pharmacokinetic data.

Review 7. Dose-dependent pharmacokinetics and cancer chemotherapy.

Review 8. Pharmacokinetic and pharmacodynamic considerations in drug therapy of cardiac emergencies.

9. The effect of propranolol on whole-body microvibrations during examination stress.

10. Clinical pharmacokinetics of buffered propranolol sublingual tablet (Promptol™)-application of a new "physiologically based" model to assess absorption and disposition.